Vivoryon Therapeutics Aktie

1,66 EUR -0,05 EUR -2,69 %

16:53:24

STU

1,71 EUR -0,01 EUR -0,70 %

17:50:05

GVIE

Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!

JETZT LOSLEGEN

Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handeln Smartphone

Marktkap.45,04 Mio. EUR

Div. Rendite0,00%

WKNA2QJV6

ISINNL00150002Q7

SymbolVIVRF

Vivoryon Therapeutics Aktien News

Sortieren:Datum Meistgelesen

27.05.25GlobeNewswireVivoryon Therapeutics N.V. Expands Intellectual Property Portfolio with New U.S. Composition of Matter Patent Granted for Varoglutamstat

13.05.25GlobeNewswireVivoryon Therapeutics N.V. to Hold its 2025 Annual General Meeting on June 24, 2025

29.04.25GlobeNewswireVivoryon Therapeutics N.V. Reports Full Year 2024 Financial Results and Provides Business Update

WerbungVivoryon Therapeutics-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero

24.04.25GlobeNewswireVivoryon Therapeutics N.V. Signs Financing Agreement for up to EUR 15 Million

17.04.25GlobeNewswireVivoryon Therapeutics N.V. to Report Full Year 2024 Financial Results and Operational Progress on April 29, 2025

19.02.25GlobeNewswireVivoryon Therapeutics N.V. Shares Highlights from Virtual R&D Update with KOL Speakers

11.02.25GlobeNewswireVivoryon Therapeutics N.V. to Host Virtual R&D Update with KOL Speakers on February 18, 2025

14.01.25GlobeNewswireVivoryon Therapeutics N.V. Provides R&D-Update Further Strengthening Development Pipeline in Kidney Disease

10.12.24GlobeNewswireVivoryon Therapeutics N.V. Reports Q3 2024 Results and Highlights Progress on Varoglutamstat in Kidney Disease

09.12.24GlobeNewswireVivoryon Therapeutics N.V. Presents Topline Phase 2 Data from VIVA-MIND Strongly Supporting Varoglutamstat’s Potential to Improve Kidney Function

04.12.24GlobeNewswireVivoryon Therapeutics N.V. to Report Q3 2024 Financial Results and Operational Progress on December 10, 2024

26.10.24GlobeNewswireVivoryon Therapeutics N.V. Presents Outstanding Phase 2b Results of Varoglutamstat on Kidney Function at ASN Kidney Week 2024

11.10.24GlobeNewswireVivoryon Therapeutics N.V. Announces Late-breaking Oral Presentation at the American Society of Nephrology Kidney Week 2024

01.10.24GlobeNewswireVivoryon Therapeutics N.V. Shares Highlights from Virtual Kidney Disease KOL Event

12.09.24GlobeNewswireVivoryon Therapeutics N.V. Reports H1 2024 Progress Marked by Compelling Kidney Function Data and Execution of Strategy to Advance Varoglutamstat in Kidney Disease

05.09.24GlobeNewswireVivoryon Therapeutics N.V. Announces Completion of Share Capital Reduction and Change to Articles of Association

05.09.24GlobeNewswireVivoryon Therapeutics N.V. to Report Half Year 2024 Financial Results on September 12, and to Host KOL Event on September 30, 2024

18.07.24GlobeNewswireVivoryon Therapeutics N.V. Announces New Data Showing Unique Treatment Effects of Varoglutamstat on Kidney Function in Patients with Diabetes and Outlines Proposed Clinical Development Plan in Diabeti

09.07.24GlobeNewswireVivoryon Therapeutics N.V. to Host R&D Update Call on July 18, 2024 Focused on Progress in Kidney Disease

21.06.24GlobeNewswireVivoryon Therapeutics N.V. Reports Outcome of 2024 Annual General Meeting

23.05.24GlobeNewswireVivoryon Therapeutics N.V. Reports Q1 2024 Financial Results and New Data Reinforcing Strategic Focus in Kidney Disease

15.05.24GlobeNewswireVivoryon Therapeutics N.V. to Report Q1 2024 Financial Results and Operational Progress on May 23, 2024

08.05.24GlobeNewswireVivoryon Therapeutics N.V. to Hold its 2024 Annual General Meeting on June 21, 2024

24.04.24GlobeNewswireVivoryon Therapeutics N.V. Reports Full Year 2023 Financial Results and Provides Varoglutamstat and Strategic Updates

16.04.24GlobeNewswireVivoryon Therapeutics N.V. to Report Full Year 2023 Financial Results and Operational Progress on April 24, 2024

15.03.24GlobeNewswireVivoryon Therapeutics N.V. Announces Changes to Board Composition

04.03.24GlobeNewswireVivoryon Therapeutics N.V. Provides Update on VIVIAD Phase 2b Study of Varoglutamstat in Early Alzheimer’s Disease

08.01.24GlobeNewswireVivoryon Therapeutics N.V. to Host Investor Meetings in January 2024

06.12.23GlobeNewswireVivoryon Therapeutics N.V. Reports Third Quarter 2023 Financial Results and Highlights Operational Progress

28.11.23GlobeNewswireVivoryon Therapeutics N.V. to Report Q3 2023 Financial Results and Operational Progress on December 6, 2023

07.11.23GlobeNewswireVivoryon Therapeutics N.V. to Present at Upcoming Investor Conference

26.10.23GlobeNewswireVivoryon Therapeutics N.V. Provides Comprehensive Progress Report for Ongoing Varoglutamstat Clinical Program Following R&D Event and VIVA-MIND DSMB Dose Decision

23.10.23GlobeNewswireVivoryon Therapeutics N.V. Reports Positive Outcome from Independent Data Safety Monitoring Board with Unanimous Decision for VIVA-MIND U.S. Study of Varoglutamstat in Alzheimer’s Disease to Proceed a

17.10.23GlobeNewswireVivoryon Therapeutics N.V. Shares Highlights from Virtual R&D Event with Key Opinion Leaders

05.10.23GlobeNewswireVivoryon Therapeutics N.V. Announces Virtual R&D Event with Key Opinion Leaders and Upcoming Conference Participation

15.09.23GlobeNewswireVivoryon Therapeutics N.V. Extraordinary General Meeting Approved Appointment of New Executive Directors to the Board

07.09.23GlobeNewswireVivoryon Therapeutics N.V. Reports H1 2023 Financial Results and Highlights Operational Progress

31.08.23GlobeNewswireVivoryon Therapeutics N.V. to Report Half Year 2023 Financial Results and Operational Progress on September 07, 2023

04.08.23GlobeNewswireVivoryon Therapeutics N.V. Extraordinary General Meeting to Confirm New Executive Director Appointments to the Board, Being Held on September 15, 2023

04.08.23GlobeNewswireVivoryon Therapeutics N.V. Announces Proposed Appointment of Dr. Frank Weber as Chief Executive Officer

Vivoryon Therapeutics News

Vivoryon Therapeutics News: auf dieser Seite finden Sie alle Vivoryon Therapeutics News und Nachrichten zur Vivoryon Therapeutics Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Vivoryon Therapeutics News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Vivoryon Therapeutics News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.